tiprankstipranks
Advertisement
Advertisement

JP:4502 Stock Latest News

Alkermes price target lowered to $43 from $45 at Piper Sandler
The FlyAlkermes price target lowered to $43 from $45 at Piper Sandler
10h ago
TAK
ALKS
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
PremiumThe Fly
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
22d ago
TAK
PTGX
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
PremiumThe Fly
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
22d ago
TAK
PTGX
Takeda and Protagonist Win FDA Priority Review for First-in-Class Polycythemia Vera Drug
PremiumCompany Announcements
Takeda and Protagonist Win FDA Priority Review for First-in-Class Polycythemia Vera Drug
22d ago
Boston Scientific names Cathy Smith, Christophe Weber to board of directors
PremiumThe Fly
Boston Scientific names Cathy Smith, Christophe Weber to board of directors
29d ago
BSX
TAK
Takeda announces data from Phase 3 KEPLER trial of ENTYVIO
PremiumThe FlyTakeda announces data from Phase 3 KEPLER trial of ENTYVIO
1M ago
TAK
Takeda granted Priority Review for oveporexton by FDA
Premium
The Fly
Takeda granted Priority Review for oveporexton by FDA
1M ago
TAK
Takeda Wins FDA Priority Review for Potential First-in-Class Narcolepsy Drug
Premium
Company Announcements
Takeda Wins FDA Priority Review for Potential First-in-Class Narcolepsy Drug
1M ago
Takeda raises FY25 core EPS view to 486 yen from 479 yen
PremiumThe Fly
Takeda raises FY25 core EPS view to 486 yen from 479 yen
2M ago
TAK
Takeda reports Q3 core EPS 428 yen vs. 443 yen last year
PremiumThe Fly
Takeda reports Q3 core EPS 428 yen vs. 443 yen last year
2M ago
TAK
Takeda Posts Lower Nine-Month Revenue but Higher Profit, Lifts Dividend and Trims Growth Outlook
PremiumCompany Announcements
Takeda Posts Lower Nine-Month Revenue but Higher Profit, Lifts Dividend and Trims Growth Outlook
2M ago
TKPHF Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
TKPHF Upcoming Earnings Report: What to Expect?
2M ago
Takeda announces U.S. availability of Gammagard Liquid ERC
PremiumThe FlyTakeda announces U.S. availability of Gammagard Liquid ERC
2M ago
TAK
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
2M ago
RR
ENB
Takeda resumed with an Overweight at Morgan Stanley
Premium
The Fly
Takeda resumed with an Overweight at Morgan Stanley
2M ago
TAK
Leerink views ‘major deal’ on Entyvio as positive for Halozyme
PremiumThe Fly
Leerink views ‘major deal’ on Entyvio as positive for Halozyme
3M ago
TAK
HALO
Halozyme announces global collaboration, license agreement with Takeda
PremiumThe Fly
Halozyme announces global collaboration, license agreement with Takeda
3M ago
TAK
HALO
Alumis price target raised to $32 from $18 at Guggenheim
PremiumThe Fly
Alumis price target raised to $32 from $18 at Guggenheim
3M ago
TAK
ALMS
Takeda, Protagonist Therapeutics submit rusfertide new drug application to FDA
PremiumThe Fly
Takeda, Protagonist Therapeutics submit rusfertide new drug application to FDA
3M ago
TAK
PTGX
H.C. Wainwright remains bullish on Xoma following creative Takeda deal
PremiumThe FlyH.C. Wainwright remains bullish on Xoma following creative Takeda deal
3M ago
TAK
XOMA
Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement
Premium
The Fly
Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement
3M ago
TAK
XOMA
Leerink says Takeda results signal positive readthrough for Alumis
Premium
The Fly
Leerink says Takeda results signal positive readthrough for Alumis
3M ago
TAK
ALMS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >